TG Therapeutics Stock
TG Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael S. Weiss
- Employees
- 399
- Market cap
- $8.3 B
- IPO
- 03/05/2010
Based in Morrisville, US, TG Therapeutics, Inc. is a healthcare company operating within the biotechnology industry. The biopharmaceutical company has advanced to the commercial stage, focusing on the acquisition, advancement, and marketing of novel therapeutic solutions. Its core focus areas include B-cell related…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
TG Therapeutics stock: price history
1D
-3.6%
1W
-2.5%
1M
-3.4%
6M
+52.8%
YTD
+81.0%
1Y
+54.8%
2Y
+120.3%
5Y
+62.0%
10Y
+719.0%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~12% stronger price swings than usual
TG Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
TG Therapeutics, Inc. is a biopharmaceutical company in the commercialization phase that specializes in the research, development, and marketing of novel therapeutic solutions. The company's focus areas are the treatment of B-cell-related cancers and various autoimmune diseases. Its portfolio includes the active pharmaceutical ingredient Ublituximab for treating lymphomas and multiple sclerosis, as well as Umbralisib for various lymphoma types. In addition to primary sales of pharmaceutical products, the company generates revenue through licensing fees and royalty payments. Business operations encompass both clinically advanced therapeutics and preclinical programs that are advanced through strategic partnerships with various partners.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about TG Therapeutics
Analyst assessment of TG Therapeutics
PRICE TARGET LOW
US$78.00
CONSENSUS
US$80.50
MEDIAN
US$80.50
PRICE TARGET HIGH
US$83.00
0
STRONG BUY
11
BUY
1
HOLD
1
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 01/09/2026
TG Therapeutics stock metrics
P/E
17.72
P/B
12.67
EV/EBITDA
63.56
RETURN ON EQUITY
1.3%
NET MARGIN
3.2%
DEBT/EQUITY
1.25
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.3%
FLOAT SHARES
135,242,262
AVG. DAILY VOLUME (30D)
1,710,310
Insider transactions (SEC)
Charney Laurence N
Charney Laurence N
Charney Laurence N
Charney Laurence N
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.6%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about TG Therapeutics stock
What does TG Therapeutics do?
TG Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael S. Weiss, the company employs around 399 people.
The IPO was on 03/05/2010; the stock trades on NASDAQ under the ticker TGTX.
What do analysts say about TG Therapeutics stock?
13 analysts rate the stock, the consensus is Buy (as of 01/09/2026).
The average price target is US$80.50, ranging from US$78.00 to US$83.00, with a median of US$80.50.
This is an external assessment, not a statement by Market Jury.
When does TG Therapeutics report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does TG Therapeutics pay a dividend?
No, TG Therapeutics currently does not pay a dividend.
Which stocks are comparable to TG Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get TG Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess TG Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.